Study of BHV-3241 in Subjects With Multiple System Atrophy

  • Interventional
  • Not Recruiting
  • NCT03952806
Eligibility Details Visit Clinicaltrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy

The purpose of this study is to compare the efficacy of BHV-3241 versus placebo in subjects with Multiple System Atrophy

Gender
All

Age Group
40 Years to 75 Years

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         1. Diagnosis of probable or possible MSA according to consensus clinical criteria (Gilman et al 2008), including subjects with MSA of either subtype (MSA-P or MSA-C).

         2. Able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps. Use of assistive devices (e.g., walker or cane) is allowed.

         3. Anticipated survival of at least 3 years at the time of Screening, as judged by the Investigator.

        Exclusion Criteria:

         1. Any condition that would interfere with the subject's ability to comply with study instructions, place the subject at unacceptable risk, and/or confound the interpretation of safety or efficacy data from the study, as judged by the Investigator.

         2. Diagnosis of neurological disorders, other than MSA.

At a Glance

National Government IDNCT03952806

IRB#IRB19-0751

Lead SponsorBiohaven Pharmaceuticals, Inc.

Lead PhysicianTao Xie

Collaborator(s)N/A

EligibilityAll
40 Years to 75 Years
Not Recruiting